U.S. Schedule I Controls on Psychedelics

U.S. Schedule I Controls on Psychedelics marked a decisive change in the status of psychedelic research and treatment: what had been investigated in clinics and, in some places, adopted as a treatment option was pushed into illegal and underground practice. The change came after research programs had already been disrupted by federal action, but the 1970 Schedule I placement made the break more severe. Its legacy includes both the loss of sanctioned research and an unresolved challenge to the medical standards used to evaluate psychedelic therapy.

Treatment Promise and Uneasy Replication

By the end of the 1950s, LSD was widely regarded in North America as a possible treatment for alcohol addiction. Research at the Saskatchewan Mental Hospital had helped persuade the provincial government to make LSD therapy a standard treatment option for alcoholics. The promise was striking, but the success also raised doubts: other clinicians considered the results too good to be credible and sought to test them under tighter controls.

In the early 1960s, a leading Canadian addiction research institute attempted a replication designed to separate the drug’s effects from other influences. Volunteers received LSD in neutral rooms. Clinicians were instructed not to engage with them apart from administering an extensive questionnaire; some participants were restrained or blindfolded. The results did not match the Saskatchewan outcomes, and more than a few participants had terrifying experiences. Critics took the replication as evidence that the treatment worked less well under rigorous conditions. Supporters argued that the conditions themselves—especially the absence of an engaged therapist and attention to set and setting—had undermined the treatment. The disagreement exposed a problem that regulation would not resolve: whether context was experimental noise to be controlled or part of the therapy’s operation.

A Dispute Over What Counts as Science

Psychedelic therapy challenged psychiatric convention not only through its claims but through its form. In place of many weeks of treatment, it could rely on a single high-dose session intended to produce a profound psychological change. That approach also recast the roles of patient and therapist. Researchers described experiences that could be classified as spiritual or mystical, while psychiatrists might interpret similar reports as symptoms of illness. The treatment therefore unsettled the boundaries between sickness and health, medicine and religion, and therapist and patient.

The emerging research standards made the problem practical as well as philosophical. Psychedelic trials are difficult to blind because participants and guides can often tell whether the drug or placebo was given. Researchers also face the difficulty of separating the chemical’s effects from expectations, the treatment relationship, and the surroundings. In conventional trials, isolating variables supports causal claims; in psychedelic therapy, those variables may help shape the experience being studied. As a result, the very features supporters considered essential to treatment could make the work appear methodologically suspect to critics.

These tensions did not mean that psychedelic research had already become impossible. They did, however, make it vulnerable at a moment when professional psychiatrists were criticizing investigators for taking the drugs themselves and for allowing mystical commitments to influence their conclusions. The field was caught between demands for conventional scientific credibility and a therapeutic model whose proposed effects could not easily be detached from spiritual experience or the conditions surrounding a session.

Research Shutdown and Schedule I Placement

The federal crackdown unfolded in stages. In April 1966, Sandoz withdrew LSD-25 from circulation, transferring most of its remaining supply to the U.S. government. The withdrawal contributed to the closure of many of the roughly seventy research programs then under way. In October, the Food and Drug Administration ordered researchers across the United States to stop their work. One program at the Maryland Psychiatric Research Center at Spring Grove continued, studying LSD and psilocybin for alcoholism, schizophrenia, and the existential distress of cancer patients until 1976; why it was allowed to survive when so many others closed remains uncertain.

The 1970 Schedule I placement deepened this rupture. The book describes the federal action as prohibiting psychedelic use for any purpose, leaving researchers and therapists without a lawful basis for continuing their work. The timing matters: the 1966 withdrawal and Food and Drug Administration order had already curtailed research, while Schedule I controls later entrenched the exclusion. Together, these actions converted a contested field of medical inquiry into a largely underground practice.

Underground Practice and the Cost of Prohibition

Some therapists continued treating patients outside sanctioned medicine. One example was Leo Zeff, who had found that psychedelics could help patients move past defenses, bring unconscious material into awareness, and reach spiritual insights, sometimes in a single session. After the 1970 controls, he decided to continue underground despite the personal strain and legal exposure he described. His practice also helped codify conventions for underground psychedelic therapy, including strict confidentiality, a prohibition on sexual contact, and the use of a ceremonial cup for administering medicine.

The contrast between sanctioned and underground practice had consequences beyond the legality of a drug. Aboveground investigators could conduct formal studies; underground guides developed protocols through practice without comparable institutional oversight. The account presents Zeff’s work as an example of knowledge continuing despite prohibition, not as a substitute for controlled evidence. The shutdown also interrupted a body of research that later investigators would have to recover and test again under contemporary standards.

Revival and an Unresolved Regulatory Challenge

The later revival of psychedelic research returned to questions that the controls had left unsettled. Modern trials have reported encouraging results, including substantial reductions in anxiety and depression among many cancer patients after psilocybin sessions. Yet the studies were small and require larger-scale replication. Early findings can be amplified by volunteer selection, unusually attentive therapists, and strong expectations; reported benefits therefore remain promising signals rather than definitive proof of a cure.

The renewed research also confronts the same methodological tension in a more formal setting. Researchers cannot easily conceal treatment allocation, and the effects of the drug may be inseparable from the guide, the participant’s expectations, and the therapeutic environment. Psychedelic-assisted psychotherapy has consequently challenged regulators to assess a treatment in which the drug appears to work partly by occasioning an experience, rather than through an effect that can be isolated from its context. The history of Schedule I controls is thus not only a story of research being stopped. It is also the history of a dispute over what medicine can recognize as evidence—and whether a treatment whose essential conditions resist isolation can meet the standards designed to isolate them.